Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

29/20/29	Aradigm Corporation Went Out of Business	CI
12/20/12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Market Cap	48.85L 42.26L 39.46L 36.2L 68.09L 46Cr 69.17L 4.63Cr 1.82Cr 23Cr 1.83Cr 1.79Cr 77Cr	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	1.28Cr 1.11Cr 1.03Cr 94.84L 1.78Cr 121.8Cr 1.81Cr 12Cr 4.76Cr 61Cr 4.81Cr 4.7Cr 201.83Cr	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

29/20/29	Aradigm Corporation Went Out of Business	CI
12/20/12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
27/20/27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
08/20/08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
31/20/31	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
30/20/30	Motion for Asset Sale Approved for Aradigm Corporation	CI
09/20/09	Bidding Procedure Approved for Aradigm Corporation	CI
21/20/21	Motion for Asset Sale Filed by Aradigm Corporation	CI
21/20/21	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
06/19/06	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
31/19/31	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
22/19/22	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19/19/19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

16/20/16	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/20/05	ARADIGM CORP : Other Events (form 8-K)	AQ
30/20/30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/20/13	ARADIGM CORP : Other Events (form 8-K)	AQ
06/20/06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.99%	+0.35%	+4.91%	+16.06%	4.87TCr
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	4.21TCr
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	3.83TCr
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	3.75TCr
CELLTRION, INC.	+2.21%	+4.89%	+17.24%	+51.64%	3.14TCr
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	1.65TCr
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	1.63TCr
EUROFINS SCIENTIFIC SE	-0.11%	+1.75%	+8.05%	+18.47%	1.4TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	1.27TCr
Average	+2.15%	+3.06%	+85.46%	+116.25%	2.86TCr
Weighted average by Cap.	+2.58%	+2.31%	+103.31%	+139.35%

Aradigm Corporation Share Price OTC Bulletin Board

Stocks

ARDM

US0385053014

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

	2016	2017
Net sales	2L 2L 2L 1L 3L 1.86Cr 3L 18.48L 7L 93.02L 7L 7L 3.08Cr	1.45Cr 1.25Cr 1.17Cr 1.07Cr 2.02Cr 137.67Cr 2.05Cr 14Cr 5.38Cr 69Cr 5.43Cr 5.31Cr 228.12Cr
Net income	-3.29Cr -2.85Cr -2.66Cr -2.44Cr -4.59Cr -313.48Cr -4.66Cr -31Cr -12Cr -157.12Cr -12Cr -12Cr -519.44Cr	-1.07Cr -92.6L -86.47L -79.33L -1.49Cr -101.88Cr -1.52Cr -10Cr -3.98Cr -51Cr -4.02Cr -3.93Cr -168.82Cr
Net Debt	-93.72L -81.07L -75.71L -69.45L -1.31Cr -89Cr -1.33Cr -8.88Cr -3.49Cr -45Cr -3.52Cr -3.44Cr -147.8Cr	79.13L 68.45L 63.92L 58.64L 1.1Cr 75Cr 1.12Cr 7.5Cr 2.94Cr 38Cr 2.97Cr 2.91Cr 124.79Cr